<DOC>
	<DOCNO>NCT00101959</DOCNO>
	<brief_summary>Brief Summary : 800 RRMS Subjects currently treat Avonex Copaxone randomize either continue current therapy receive Rebif therapy . The subject follow 2 year . The primary objective compare time worsen medium level concern define Canadian Multiple Sclerosis Working Group ( CMSWG ) treatment optimization recommendation .</brief_summary>
	<brief_title>Implementation Study Treatment Optimization Recommendations Relapsing-Remitting Multiple Sclerosis ( RR MS ) Subjects</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Written inform consent ( HIPAA authorization USA subject ) studyrelated procedure , part subject 's normal medical care , understand subject could withdraw consent time without prejudice future medical care Age 18 60 year ( inclusive ) Male female subject clinically definite laboratorysupported definite relapsingremitting multiple sclerosis base Poser McDonald criterion Results MRI scan acquire within 2 year screen , consistent MS . Duration MS ≤ 7 year onset symptom Receiving consistent therapy Avonex® , Copaxone® ≥ 2 year ( Subjects convert one therapy another use diseasemodifying therapy ( DMTs ) within two year Screening exclude ) . Expanded Disability Status Score ( EDSS ) 0 ≤ 5.5 , inclusive Exhibiting low medium level concern base number severity relapse within 12 month prior screen ( subject reach high level concern time within past 12 month exclude ) ; *Low Level Concern : ) 1 mild relapse ( Mild severity corticosteroid require , minimal effect Activities Daily Living ( ADL ) , 1 Kurtzke Functional Systems ( KFS ) functional domain affect , mild motor/cerebellar involvement , need treatment hospitalization prompt recovery ) ; *Medium Level Concern : ) 2 mild relapse 1 moderate relapse ( Moderate severity corticosteroid may require , moderate effect ADL , &gt; 1 KFS functional domain may affect , moderate motor/cerebellar involvement , may require treatment hospitalization incomplete recovery 3 month complete recovery 6 month ) Clinical stability improve neurological state eight week Study Day 1 Willingness ability comply protocol duration study If female , must either : 1. postmenopausal surgically sterilize ; 2. use hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , duration study ; 3. neither pregnant breastfeeding . 4. confirmation subject pregnant must establish negative serum hCG pregnancy test within 30 day Study Day 1 negative urine pregnancy test Study Day 1 . A pregnancy test require female childbearing potential . The small minority subject Rebif therapy reimburse insurance carrier may consider study otherwise eligible , require prior approval sponsor coverage cost Rebif therapy Pregnant lactate woman , woman childbearing potential use acceptable method contraception Progressive form MS ( Primary progressive , Secondary progressive ) Exhibiting high level concern base number severity relapse time 12 month prior screen ; *High Level Concern ) 3 mild , 2 moderate 1 severe relapse ( Severe Severity Corticosteroids hospitalization require , severe effect ADL , &gt; 1 KFS functional domain may affect , severe motor/cerebellar involvement , impact ADL incomplete recovery 6 month ) Subjects DMTs Avonex® Copaxone® two year prior screen . Subjects history intolerance Interferon Beta History hypersensitivity natural recombinant interferon beta , human serum albumin , component Rebif® formulation include mannitol History hypersensitivity natural recombinant interferon beta , human serum albumin , component Rebif® formulation include mannitol Participation study involve investigational market product , concomitantly within 3 month prior Study Day 1 Treatment oral systemic corticosteroid ACTH within 4 week Study Day 1 ongoing chronic treatment systemic corticosteroid . Treatment immunomodulatory immunosuppressive therapy ( include limit cyclophosphamide , cyclosporine , methotrexate , azathioprine , linomide , mitoxantrone , Campath ) within 12 month prior Study Day 1 Prior cytokine anticytokine therapy within 3 month prior Study Day 1 Prior use cladribine receive total lymphoid irradiation Prior use Antegren® ( natalizumab ) Have take intravenous immunoglobulin investigational drug take part experimental procedure 3 month prior Study Day 1 Psychiatric disorder unstable would preclude safe participation study Cognitive impairment impairs ability understand comply protocol procedures Any laboratory value reach Grade 2 toxicity great within 30 day Study Day 1 base Common Terminology Criteria Adverse Events ( CTACE ) criteria Specific systemic disease , ( include insulindependent diabetes , Lyme disease , clinically significant cardiac disease , HIV , HTLV1 , Hepatitis B C ) , uncontrolled major medical condition ( depression , seizure disorder ) would interfere participant 's safety , compliance evaluation Unable and/or unlikely follow protocol reason Alcohol and/or drug abuse Likelihood require treatment study period drug permit study protocol Abnormal baseline clinical finding consider investigator indicative condition might affect study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>